Short answer
ORASURE TECHNOLOGIES INC (OSUR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). OraSure announced consolidated results for the quarter ended September 30, 2026.
ORASURE TECHNOLOGIES INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- OraSure announced consolidated results for the quarter ended September 30, 2026
- Detailed financial results and management commentary are contained in Exhibit 99.1
- Investors should review the exhibit for revenue, profitability, guidance and operating trends
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $30.9M, up 14% year over year, led by Diagnostics growth of 16% and Sample Management Solutions growth of 21%
- GAAP gross margin expanded to 45.2% from 43.5%, reflecting operational efficiencies and improved fixed-cost absorption
- GAAP operating loss narrowed to $13.0M from $16.1M, but non-GAAP net loss widened to $10.1M from $9.8M
- Initial orders for Colli-Pee Dx and OraQuick Ebola 2.0 create early commercial validation for new growth platforms
- Q4 revenue guidance $30.0M to $32.0M, with full-year 2027 growth expected to accelerate; cash totaled $148.2M at September 30, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ORASURE TECHNOLOGIES INC 8-K filings
Get the next OSUR 8-K as it lands
Follow OSUR for push alerts, or ask the research agent what this filing means.